Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Ponatinib + venetoclax for the treatment of R/R Ph+ALL

Farhad Ravandi • 11 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Ponatinib Venetoclax

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and key findings of a study evaluating the safety and efficacy of ponatinib plus venetoclax in patients with relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) (NCT03576547). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding – BMS/Celgene, Amgen, Astex/Taiho, Syros, Prelude, Abbvie, Xencor Consultant – BMS, Abbvie, Novartis, AstraZeneca, Taiho, Jazz

More from Farhad Ravandi

1:23
The value of MRD as a marker for disease eradication in AML
Farhad Ravandi • 8 Dec 2023
1:31
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi • 8 Dec 2023
1:29
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi • 8 Dec 2023
1:43
Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL
Farhad Ravandi • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals